Stability and Sterility of Bevacizumab after Withdrawal into a Syringe and Refrigeration or Freezing

Published on Oct 1, 2014in Journal of The Korean Ophthalmological Society
· DOI :10.3341/JKOS.2014.55.10.1499
Gwang Myung Noh1
Estimated H-index: 1
(Kosin University),
Soo Young Kim58
Estimated H-index: 58
+ 3 AuthorsSang Joon Lee11
Estimated H-index: 11
(Kosin University)
Purpose: The aim of this study was to evaluate the stability and sterility of bevacizumab (Avastin, Genentech, Inc., San Francisco, CA, USA) after withdrawal into multiple doses from single-use vials. Methods: Bevacizumab was repeatedly and aseptically drawn from new vials into 1 cc plastic syringes and refrigerated in the dark at 4°C for 0, 3, 6, 12, 28, 38, 46, 52, or 63 weeks or at -10°C for 0, 3, 6, 12, 38, 46, or 52 weeks. The stability of bevacizumab was assessed by enzyme-linked immunosorbent assay (ELISA) and compared with that of controls (0 weeks). The contents of the fractionated bevacizumab syringes were analyzed for microbial growth. Results: When we assessed the relative stability of the bevacizumab stored at 4°C, there was no concentration change for up to 12 weeks. However, concentration decreased by less than 2% between 28 weeks and 46 weeks. Samples stored at -10°C were stable up to 52 weeks. All of the fractionated syringes maintained >90% stability compared with controls for up to one year in both the refrigerated group and the frozen group. The microbial study showed no significant positive results for up to 12 weeks. After intravitreal bevacizumab injection, the statuses of all patients improved, with no signs of intraocular infection. We observed no cases of intraocular infection or complications among the patients. Conclusions: Fractionating and storing smaller amounts from single-use vials is a safe method for intravitreal bevacizumab injection. J Korean Ophthalmol Soc 2014;55(10):1499-1503
📖 Papers frequently viewed together
17 Citations
16 Citations
Purpose: The aim of this study was to determine the sterility, stability, and efficacy of a commercially available brand of bevacizumab for 6 months of being stored in multidose vials at 4°C.Methods: Bevacizumab was aseptically and repeatedly drawn four to five times from new vials into syringes for clinical use within the first month; the remaining bevacizumab was left in the vials and refrigerated at 4°C for 0, 1, 3, and 6 months for research. Each time before bevacizumab was withdrawn and eve...
22 CitationsSource
#1Kemal Örnek (Kırıkkale University)H-Index: 15
#2Zeynep Ceren Karahan (Ankara University)H-Index: 9
Last. Oya Tekeli (Ankara University)H-Index: 14
view all 5 authors...
Background:Recent reports have demonstrated that refrigerated bevacizumab can be stored for up to 3 weeks at 4 °C without loss of efficacy. There have been no previous reports addressing bevacizumab's sterility when stored and used as multiple doses from a single-use vial.Objective:To evaluate the sterility of bevacizumab when used as multiple doses from a single-use vial.Methods:Four groups of vials were used to simulate the storage and use conditions for bevacizumab. Each group contained 11 do...
18 CitationsSource
Background: Bevacizumab is an anti-angiogenic compound developed to target tumor vessels. Off-label use in ophthalmology requires in vitro testing on ocular cells. Consequently we quantified the anti-permeability and anti-proliferative effect of bevacizumab on cultured choroidal endothelial cells. It was examined whether deep-freezing of bevacizumab attenuates its anti- angiogenic activity. Methods: Porcine choroidal endothelial cells (CEC) were cultured in permeable insert systems. Permeability...
67 CitationsSource
#1Pradeepa Yoganathan (North Shore-LIJ Health System)H-Index: 5
#2Vincent A. DeramoH-Index: 14
Last. David M. FastenbergH-Index: 9
view all 5 authors...
PURPOSE: To study the visual and anatomic outcome of intravitreal bevacizumab injection in the treatment of exudative age-related macular degeneration (AMD). METHODS: Retrospective review of patients who received one or more intravitreal bevacizumab injections for exudative AMD. Outcome measures include standardized visual acuity, optical coherence tomography (OCT), macular thickness and volume, intraocular pressure, and blood pressure at 24 or more weeks follow-up. RESULTS: Fifty eyes of 48 pat...
151 CitationsSource
#1Rodrigo Jorge (USP: University of São Paulo)H-Index: 28
#1Rodrigo Jorge (USP: University of São Paulo)H-Index: 10
Last. Ingrid U. ScottH-Index: 96
view all 5 authors...
Objective: To evaluate the short-term fluorescein angiographic and visual acuity effects of a single intravitreal injection of bevacizumab (Avastin) for the management of persistent new vessels (NV) associated with diabetic retinopathy. Methods: A prospective, nonrandomized open-label study of diabetic patients with actively leaking NV refractory to laser treatment and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity (BCVA) worse than 20/40. Standardized ophthalmic evaluat...
315 CitationsSource
#1Christos Haritoglou (LMU: Ludwig Maximilian University of Munich)H-Index: 53
#2Daniel KookH-Index: 24
Last. Anselm KampikH-Index: 73
view all 9 authors...
Purpose:To evaluate the efficacy of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) for the treatment of diabetic macular edema.Methods:This prospective, consecutive, noncomparative case series included 51 consecutive patients (26 females and 25 males; mean age, 64 years) with diffus
567 CitationsSource
#1Sophie J. Bakri (Mayo Clinic)H-Index: 43
#2Melissa R. Snyder (Mayo Clinic)H-Index: 29
Last. Ravinder J. Singh (Mayo Clinic)H-Index: 77
view all 6 authors...
Purpose:To determine the change in anti–vascular endothelial growth factor (VEGF) activity of bevacizumab (Avastin, Genentech, Inc., San Francisco, CA) after refrigeration or freezing.Methods:Samples of bevacizumab were drawn up from new vials into plastic tuberculin syringes and refrigerated at 4°C
122 CitationsSource
Purpose: To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with macular edema due to central retinal vein occlusion (CRVO). Methods: The authors conducted a retrospective study of patients with macular edema due to CRVO who were treated with at least one intravitreal injection of bevacizumab 1.25 mg in 0.05 mL. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging, and o...
656 CitationsSource
#1Herbert Hurwitz (Duke University)H-Index: 80
#2Louis Fehrenbacher (KP: Kaiser Permanente)H-Index: 69
Last. Fairooz F. Kabbinavar (UCLA: University of California, Los Angeles)H-Index: 62
view all 15 authors...
background Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. methods Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placeb...
11.8k CitationsSource
Cited By1